A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Related Posts
Long GV, Khattak MA, Gogas HJ, Schadendorf D, Arance A, Carlino MS, Rutkowski P, Rivalland G, Ribas A, Mehnert JM, Ott PA, Dummer R, Queirolo[...]
Garassino MC, Ahn MJ, Schick M, Kapil A, Paz-Ares L, Lisberg A, Johnson ML, Pérol M, Shimizu T, Heist R, Spira A, Okamoto I, Girard[...]
Sarkar S, Sedrak MS, Carroll JE, Schechter C, Muss HB, Mandelblatt JS. Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Netw[...]